Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: redbird who wrote (27326)	6/8/2000 9:29:00 AM
From: BANCHEE	Respond to of 57584

redbird NEXL...up over 5 in pre market.."exclusive license" Thursday June 8, 8:09 am Eastern Time Company Press Release Nexell Therapeutics Obtains Exclusive License to Antibody Portfolio in New Agreement With Diaclone Nexell Also Receives Right of First Refusal for In Vivo Applications IRVINE, Calif.--(BW HealthWire)--June 8, 2000--Nexell Therapeutics Inc. (Nasdaq: NEXL - news), one of the world's leading suppliers of therapeutic and diagnostic products based on stem cell technology, announced today that it has converted its worldwide licensing agreement with Diaclone, SA, to an exclusive license for six monoclonal antibodies for use in ex vivo cell therapy. In January, the companies announced an agreement granting Nexell Therapeutics non-exclusive rights to this portfolio. The agreement also gives Nexell Therapeutics right of first refusal for potential in vivo applications of these antibodies, such as treatment of graft versus host disease (GVHD) with CD25. biz.yahoo.com Banchee